Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Operating Leases (2019 - 2025)

Historic Operating Leases for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to $183746.0.

  • BioNexus Gene Lab's Operating Leases rose 301.57% to $183746.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $183746.0, marking a year-over-year increase of 301.57%. This contributed to the annual value of $210557.0 for FY2024, which is 5784.47% up from last year.
  • As of Q3 2025, BioNexus Gene Lab's Operating Leases stood at $183746.0, which was up 301.57% from $197156.0 recorded in Q2 2025.
  • BioNexus Gene Lab's Operating Leases' 5-year high stood at $210557.0 during Q4 2024, with a 5-year trough of $14118.0 in Q3 2022.
  • Its 5-year average for Operating Leases is $94754.4, with a median of $56775.0 in 2022.
  • In the last 5 years, BioNexus Gene Lab's Operating Leases crashed by 5076.72% in 2022 and then soared by 64278.93% in 2023.
  • Over the past 5 years, BioNexus Gene Lab's Operating Leases (Quarter) stood at $42909.0 in 2021, then soared by 32.31% to $56775.0 in 2022, then surged by 134.95% to $133395.0 in 2023, then soared by 57.84% to $210557.0 in 2024, then dropped by 12.73% to $183746.0 in 2025.
  • Its last three reported values are $183746.0 in Q3 2025, $197156.0 for Q2 2025, and $200113.0 during Q1 2025.